90P ERLOTINIB VS CHEMOTHERAPY AS SECOND LINE THERAPY FOR PATIENTS WITH ADVANCED EGFRWT NON SMALL CELL LUNG CANCER. A SINGLE INSTITUTION EXPERIENCE | Publicación